Growing Awareness of Lymphedema to Drive the India Lymphedema Treatment Market
According to our new research study on "India Lymphedema Treatment Market Size and Forecast (2020–2030), Country Share, Trend, and Growth Opportunity Analysis – by Condition Type, Treatment Type, and End User," the market is expected to grow from US$ 926.65 million in 2022 to US$ 1,511.06 million by 2030; it is estimated to record a cagr of 6.3% from 2022 to 2030.
Every year on March 6, the National Lymphedema Network and lymphedema community nationwide celebrate Lymphedema Awareness "D" Day. The main goal of such programs is to show the world that lymphedema is no longer a rare condition by honoring the majority of the population living today and the exceptional healthcare providers for their dedication and support.
India Lymphedema Treatment Market Forecast (2020-2030), and Country Share, Trend, and Growth Opportunity Analysis Coverage: Condition Type (Primary Lymphedema and Secondary Lymphedema), Treatment Type [Compression Devices and Bandaging, Drug Therapy, Physiological Procedure (Lymphovenous Anastomosis and Vascularized Lymph Node Transfer), Debulking Procedure, and Others], and End User (Hospitals, Clinics, Clinical Research Organizations, and Others))
India Lymphedema Treatment Market to Grow at a CAGR of 12.29% to reach US$ 1,511.06 million from 2022 to 2030
Download Free Sample
In 2023, India adopted the "enhance" strategy for eliminating lymphatic filariasis, which has five pillars of interventions. One of the key pillars is the mission mode Mass Drug Administration (MDA). The other four pillars of the enhanced strategy are morbidity management and disability prevention, vector control, high-level advocacy, and innovative approaches. These five pillars of interventions in the enhanced strategy are based upon a solid foundation of evidence and learnings from past experiences, such as polio and measles elimination efforts in India.
Additionally, in August 2023, the Union Health & Family Welfare Minister announced the elimination of lymphatic filariasis by 2027 during the inauguration of the second phase of the Annual Nationwide MDA initiative. With a focal point on 81 districts spread across nine endemic states, including Assam and Uttar Pradesh, this second phase marks a significant step forward in the battle against the crippling disease. Minister emphasized the comprehensive approach of “Whole of Government” and “Whole of Society” to combat lymphatic filariasis effectively.
In December 2021, the Government of India implemented a program to eliminate lymphedema. The National Centre for Vector Borne Diseases Control (NCVBDC) administers an umbrella program—the National Vector Borne Diseases Control Programme (NVBDCP)—to prevent and control vector diseases. Under NVBDCP, filaria, malaria, and Kala-Azar are the three diseases under the elimination program. .
Thus, the growing awareness about lymphedema is driving the market of its treatment in India.
India lymphedema treatment market is segmented as follows:
The India lymphedema treatment market, by condition type, is segmented into primary lymphedema and secondary lymphedema. The secondary lymphedema segment held a larger share of the market in 2022. The primary lymphedema segment is anticipated to register a higher CAGR during 2022–2030. Secondary lymphedema's significant share is usually attributed to cancer-related treatment, which is a prominent cause of secondary lymphedema. Primary lymphedema is a rare chronic pathology associated with constitutional abnormalities of the lymphatic system. For instance, the Frontiers S.A. report states that primary lymphedema can appear at age 35 and is also referred to as lymphedema tarda. Additionally, the incidence of primary lymphedema is low, affecting 1 in 100,000 people worldwide. Primary lymphedema is also strongly linked to acquired lymphedema and has genetic mutations causing primary lymphedema. For example, breast cancer patients carrying acquired lymphedema have higher genetic variation, called single nucleotide polymorphisms (SNPs), in the same genes causing primary lymphedema. Such factors positively influence the overall growth of the segment during the analysis period.
Essity AB, Lympha Press USA Ltd, AIROS Medical Inc, 3M Co, Bio Compression Systems Inc, Lohmann & Rauscher GmbH & Co KG, Huntleigh Healthcare Ltd, Dynamic Techno Medicals Pvt Ltd, Medi GmbH & Co KG, Datt Mediproducts Pvt Ltd, Smith & Nephew Plc, SIGVARIS Management AG, and Tactile Systems Technology Inc. are among the leading companies operating in India lymphedema treatment market.
Industry Developments and Future Opportunities:
Various initiatives taken by key players operating in the India lymphedema treatment market are listed below:
KOB GmbH launched its two products at MEDICA Trade Fair 2022. With this 2-component system, the company expanded its product portfolio of compression bandages. VisioCompress2 Lite is used when a lower compression pressure is required. Like the proven VisioCompress2 multi-layer system, VisioCompress2 Lite consists of a padding and permanently elastic non-woven bandage.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com